Kennedy Capital Management, Inc. Nektar Therapeutics Transaction History

Kennedy Capital Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	SELL	$30.43 - $56.65 $1.59 Million - $2.95 Million	-52,099 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $82,559 - $121,706	1,777 Added 3.53%	52,099 $3.18 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $2 Million - $4.51 Million	-43,137 Reduced 46.16%	50,322 $2.46 Million
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $10.8 Million - $20.3 Million	-187,409 Reduced 66.72%	93,459 $9.93 Million
Q4 2017 Feb 13, 2018	SELL	$23.02 - $60.5 $1.93 Million - $5.08 Million	-83,888 Reduced 23.0%	280,868 $16.8 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $6.49 Million - $8.75 Million	364,756	364,756 $8.75 Million

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $212M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.